Could propranolol be beneficial in adult cerebral cavernous malformations?
Caroline ApraChloé DumotPierre BourdillonIsabelle Pelissou-GuyotatPublished in: Neurosurgical review (2019)
Surgery is the only therapeutic option for cerebral cavernous malformations (CCM) and is proposed, whenever possible, after haemorrhagic events, neurological symptoms, or epilepsy, radiosurgery being a controversial alternative in some cases. However, there is no treatment for non-accessible lesions, such as brainstem CCM, multiple CCM, or those located in functional areas. Propranolol, a non-selective beta-blocker used as first-line treatment for infantile haemangiomas, has proved spectacularly effective in a few cases of adult patients with CCM. We herein review the histological, in vitro data and clinical findings that support the idea of propranolol as a potential treatment for CCM. Since one retrospective study has not been conclusive, we support the idea that prospective trials are necessary.
Keyphrases
- minimally invasive
- subarachnoid hemorrhage
- electronic health record
- acute coronary syndrome
- cerebral ischemia
- risk assessment
- combination therapy
- climate change
- coronary artery disease
- coronary artery bypass
- replacement therapy
- angiotensin ii
- data analysis
- angiotensin converting enzyme
- smoking cessation
- brain metastases